Nanoneuroprotection against glutamatergic excitotoxicity in ischemic stroke
Blood/brain-glutamate grabbing is an emerging concept in the treatment of acute ischemic stroke, where the deleterious effects of glutamate after ischemia are ameliorated by coaxing glutamate to enter the bloodstream and thus reducing its concentration in the brain. In this Thesis we resorted to a d...
| Autor: | |
|---|---|
| Formato: | tesis doctoral |
| Fecha de publicación: | 2018 |
| País: | España |
| Recursos: | Universidad de Santiago de Compostela (USC) |
| Repositorio: | Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela |
| Idioma: | inglés |
| OAI Identifier: | oai:minerva.usc.gal:10347/18044 |
| Acesso em linha: | http://hdl.handle.net/10347/18044 |
| Access Level: | acceso abierto |
| Palavra-chave: | Materias::Investigación::32 Ciencias médicas::3205 Medicina interna::320507 Neurología Materias::Investigación::24 Ciencias de la vida::2411 Fisiología humana::241111 Neurofisiología |
| Resumo: | Blood/brain-glutamate grabbing is an emerging concept in the treatment of acute ischemic stroke, where the deleterious effects of glutamate after ischemia are ameliorated by coaxing glutamate to enter the bloodstream and thus reducing its concentration in the brain. In this Thesis we resorted to a drug-repositioning strategy for the discovery of new glutamate-grabbing drugs, aiming to demonstrate the preclinical and clinical effect in ischemic stroke. The use of nanoparticles has emerged as a need to provide treatments for personalized nanomedicine through specific interactions at molecular levels. In this Thesis we optimize the active targeting of nanoparticles to an inducible target of endothelial cells in different experimental conditions of increasing complexity and tested the biocompatibility of new mesoporous nanostructures for drug delivery and contrast agent. |
|---|